PROCEPT BioRobotics (PRCT) analyst forecast and price target
Analyst forecast
Consensus of 15 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Initiated Coverage | Overweight | $30.00 | Oct 7, 2026 |
| William Blair | Downgraded | Outperform → Market Perform | — | Aug 5, 2026 |
| Evercore ISI Group | Maintained | Outperform | $23.00 from $30.00 | Aug 5, 2026 |
| Piper Sandler | Maintained | Overweight | $25.00 from $35.00 | Aug 5, 2026 |
| TD Cowen | Maintained | Buy | $28.00 from $34.00 | Aug 5, 2026 |
| UBS | Initiated Coverage | Buy → Neutral | $20.00 | Jul 28, 2026 |
| Truist Securities | Downgraded | Buy → Hold | $25.00 from $30.00 | Jul 6, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $30.00 | Jun 24, 2026 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $29.00 from $31.00 | Jun 11, 2026 |
| Piper Sandler | Maintained | Overweight | $35.00 from $28.00 | Apr 30, 2026 |
| Baird | Initiated Coverage | Neutral | $30.00 | Mar 6, 2026 |
| Truist Securities | Maintained | Buy | $30.00 from $47.00 | Mar 2, 2026 |
| B of A Securities | Downgraded | Neutral → Underperform | $20.00 from $38.00 | Feb 26, 2026 |
| Wells Fargo | Maintained | Overweight | $34.00 from $51.00 | Feb 26, 2026 |
| Piper Sandler | Maintained | Overweight | $28.00 from $50.00 | Feb 26, 2026 |
| Oppenheimer | Downgraded | Outperform → Perform | — | Feb 26, 2026 |
| TD Cowen | Maintained | Buy | $34.00 from $50.00 | Feb 26, 2026 |
| Leerink Partners | Maintained | Outperform | $30.00 from $55.00 | Feb 26, 2026 |
| Truist Securities | Maintained | Buy | $47.00 from $50.00 | Dec 18, 2025 |
| UBS | Initiated Coverage | Buy | $62.00 | Dec 12, 2025 |
Frequently asked questions
What is the price target for PRCT stock?
The average 12-month analyst price target for PROCEPT BioRobotics (PRCT) is $25.20, with a high estimate of $30.00 and a low of $20.00, across 5 analysts.
Is PRCT a buy, sell, or hold?
Analysts covering PROCEPT BioRobotics currently average a Hold rating: 4 buy, 10 hold and 1 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PRCT?
The average price target of $25.20 implies 43.92% upside from the last price of $17.51.
What is the latest analyst rating on PRCT?
On Oct 7, 2026, Barclays initiated coverage of PROCEPT BioRobotics at Overweight with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.